Cargando…
Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830408/ https://www.ncbi.nlm.nih.gov/pubmed/31172449 http://dx.doi.org/10.1007/s40273-019-00815-3 |
_version_ | 1783465776228859904 |
---|---|
author | Wallace, Katrine Goble, Sandra Isaacson, Jeff Maloney, Lara Cameron, Terri Bedel, Josh |
author_facet | Wallace, Katrine Goble, Sandra Isaacson, Jeff Maloney, Lara Cameron, Terri Bedel, Josh |
author_sort | Wallace, Katrine |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-6830408 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-68304082019-11-20 Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States” Wallace, Katrine Goble, Sandra Isaacson, Jeff Maloney, Lara Cameron, Terri Bedel, Josh Pharmacoeconomics Letter to the Editor Springer International Publishing 2019-06-07 2019 /pmc/articles/PMC6830408/ /pubmed/31172449 http://dx.doi.org/10.1007/s40273-019-00815-3 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Letter to the Editor Wallace, Katrine Goble, Sandra Isaacson, Jeff Maloney, Lara Cameron, Terri Bedel, Josh Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States” |
title | Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States” |
title_full | Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States” |
title_fullStr | Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States” |
title_full_unstemmed | Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States” |
title_short | Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States” |
title_sort | comment on: “cost-effectiveness of niraparib versus routine surveillance, olaparib and rucaparib for the maintenance treatment of patients with ovarian cancer in the united states” |
topic | Letter to the Editor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830408/ https://www.ncbi.nlm.nih.gov/pubmed/31172449 http://dx.doi.org/10.1007/s40273-019-00815-3 |
work_keys_str_mv | AT wallacekatrine commentoncosteffectivenessofniraparibversusroutinesurveillanceolaparibandrucaparibforthemaintenancetreatmentofpatientswithovariancancerintheunitedstates AT goblesandra commentoncosteffectivenessofniraparibversusroutinesurveillanceolaparibandrucaparibforthemaintenancetreatmentofpatientswithovariancancerintheunitedstates AT isaacsonjeff commentoncosteffectivenessofniraparibversusroutinesurveillanceolaparibandrucaparibforthemaintenancetreatmentofpatientswithovariancancerintheunitedstates AT maloneylara commentoncosteffectivenessofniraparibversusroutinesurveillanceolaparibandrucaparibforthemaintenancetreatmentofpatientswithovariancancerintheunitedstates AT cameronterri commentoncosteffectivenessofniraparibversusroutinesurveillanceolaparibandrucaparibforthemaintenancetreatmentofpatientswithovariancancerintheunitedstates AT bedeljosh commentoncosteffectivenessofniraparibversusroutinesurveillanceolaparibandrucaparibforthemaintenancetreatmentofpatientswithovariancancerintheunitedstates |